

Foresight study on European stakeholder appraisal of diagnostics to manage anti-microbial resistance

A brief Introduction to ongoing research

by Dr Michael Hopkins

SPRU – Science Policy Research Unit

Main research questions


(a) What kinds of diagnostics do stakeholders want in order to manage AMR?

A pan-European survey of stakeholders to understand their preferred diagnostic solutions, the attributes of these and most acceptable trade-offs for different situations.

(b) What are the policy options favoured by stakeholders to explore how diagnostics could be used to deliver progress in managing AMR

Structured interviews with stakeholders to discuss policies (such as funding or incentives) needed to ensure diagnostics are developed and used appropriately.

Pan-European discrete choice experiment survey on diagnostic trade-offs and choices



- **Focus:** on best practice guidelines for conducting DCE surveys (robustness), publications of interest to a wide range of audiences
- **Limitations:** the optimal number of attributes (3-4); survey response bias, complex survey (respondent fatigue)
- **Tensions:** Need to balance optimal time/ number of questions for email survey; broad vs. deep coverage of AMR landscape

The challenge and next steps

Over the next few weeks we are seeking to agree access to gatekeepers for the relevant stakeholder groups (trade associations, professional bodies) to allow survey of primary care and hospital-based physicians, clinical scientists, diagnostics firms, HTA experts/ healthcare payors, patients, and pharmacists, in our target countries (France, Germany, Greece, Italy, Spain, the UK, the Netherlands).

If you are interested in how new diagnostics for AMR can best be developed for different healthcare systems, please do contact us.

Michael Hopkins

m.m.hopkins@sussex.ac.uk

Project deliverables

1. Address gaps in knowledge, based on views of European stakeholders
2. An accessible policy report – to be widely disseminated
3. A web resource to share findings in an interactive manner
4. Stakeholder engagement across Europe
5. Devise and test our methods in readiness for use beyond the EU

Engagement and dissemination

Throughout the project we will engage with a wide range of stakeholders including: diagnostics firms, VC investors, primary care and hospital-based clinicians, clinical scientists, payors, patient groups, funders of research and research scientists, across European countries.

- Bilateral meetings with stakeholders throughout the project
- Targeted conference presentations to relevant audiences
- Results workshops in Europe
- Outputs made available in academic publications
- Exploration of interest in other regions for similar research